Ondansetron oral dispersible film

Drug Profile

Ondansetron oral dispersible film

Alternative Names: Ondansetron ODF; Ondansetron ODFS; Ondansetron oral soluble film; Thin film ondansetron; Zuplenz

Latest Information Update: 22 Sep 2016

Price : $50

At a glance

  • Originator MonoSol Rx LLC
  • Class Antiemetics; Antipsychotics; Carbazoles; Imidazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting; Radiotherapy-induced nausea and vomiting

Most Recent Events

  • 21 Sep 2016 Midatech Pharma and R-Pharm agree to co-promote ondansetron in USA
  • 15 Mar 2016 Biomarkers information updated
  • 18 Dec 2015 Galena Biopharma enters into sale agreement with Midatech Pharma for the sale of ondansetron oral soluble film
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top